![Hani N. Sabbah](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Hani N.
Sabbah is the founder of G3 Pharmaceuticals, Inc. He is currently working as a Director at MateraCor, Inc.
Actieve functies van Hani N. Sabbah
Bedrijven | Functie | Begin |
---|---|---|
MateraCor, Inc.
![]() MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Hani N. Sabbah
Bedrijven | Functie | Einde |
---|---|---|
G3 Pharmaceuticals, Inc.
![]() G3 Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology G3 Pharmaceuticals, Inc. is a development-stage biopharmaceutical company. It manufactures and develops galectin-3 biology, cardiovascular pharmaceutical and carbohydrate drugs. The company is headquartered in Lexington, MA. | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
G3 Pharmaceuticals, Inc.
![]() G3 Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology G3 Pharmaceuticals, Inc. is a development-stage biopharmaceutical company. It manufactures and develops galectin-3 biology, cardiovascular pharmaceutical and carbohydrate drugs. The company is headquartered in Lexington, MA. | Health Technology |
MateraCor, Inc.
![]() MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Health Technology |